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Abstract 
Alzheimer’s is a chronic neurodegenerative disease developed due to multiple cognitive deficits that 
progressively leads to at least one of the following: apraxia, aphasia, agnosia or a disturbance in executive 
functioning. As of 2012, more than 5.1 million Americans are affected by Alzheimer’s. Alzheimer’s disease 
accounts for 60 to 80 percent of dementia cases. Numerous pharmaceutical market leaders attempt on 
developing a cure for the disease. Significant progress has been made on this field. However, studies have 
shown that manual assessment of the disease using various parameters including (but not restricted 
to) Neuroimaging (MRI, PET, etc.), Neuropsychological tests (MMSE, FAQ, GDS, NPI, etc.) and 
Neurogenetics (TOMM40 gene assessment) yield an accuracy of 96% only. Our study involved integrating all 
three results and allowing the system to predict whether a patient is suffering from Alzheimer's. 
Keywords: Alzheimer’s medical care; Machine Learning approach to improve prediction accuracy; Integrating 
neuroimaging; neuropsychological; neurochemical and neurogenetics results for effective assessment. 
1. Introduction  
Accurate analysis of Alzheimer’s can aid physicians to provide proper healthcare support and medication for 
patients suffering from Alzheimer’s. Alzheimer’s is generally characterized by synthesis of large quantities of 
intraneuronal neurofibrillary tangles containing Tau proteins and extracellular amyloid plaques containing the 
peptide β amyloid. Drugs like Memantine. 
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Donepezil, Rivastigmine and galantamine are generally prescribed for Alzheimer’s patients. Memantine reduces 
the effects of glutamate, which is produced in larger quantities in patients suffering from Alzheimer’s [2]. 
Prescribing memantine for patients misdiagnosed with Alzheimer’s will have severe side-effects. Patients 
having Mild Cognitive Impairment (MCI) and are above the age of 45 are often misinterpreted with 
Alzheimer’s. Separate studies reveal that 18.18% of the patients misdiagnosed with Alzheimer’s are often given 
wrong medication. 
The paper discusses how the machine learning approach can help overcome these problems: 
• How do we interpret significant results in terms of numbers from neuropsychological, neurogenetic and 
neuroimaging tests? 
• How do we develop a machine learning model that utilizes the three test results to improve the 
accuracy of Alzheimer’s prediction? 
High level architecture of the system 
 
Figure 1: High level architecture of the machine learning model 
1.1. Objectives of this scientific paper 
- Use algorithms to process the neuroimaging, neuropsychological and neuro-genetic datasets. 
- Devise a system to integrate significant features from the three datasets. 
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- Predict Alzheimer’s using the random forest classifier hypothesis. 
2. Using algorithms to process the three datasets 
The system will consider four primary neuropsychological test scores suggested by Alzheimer’s association. 
The four tests include: 
• MMSE : Mini Mental State Exam  
Scores range from 0 to 30. Less than 26 indicates Alzheimer's 
• FAQ : Functional Activities Questionnaire 
Response for 10 questions are recorded. Each question takes values ranging from 0 to 3 [3]. 
Scores range from 0 to 30. A cut-point of 9 (dependent in 3 or more activities) is recommended. 
  • Dependent = 3       • Requires assistance = 2     • Has difficulty, but does by self = 1   • Normal = 0  
• GDS : Geriatric Depression Scale 
Response for 10 questions are recorded. Each question takes values ranging from 0 to 3. 
• 1–4 No cause for concern • 5–9 Strong probability of depression • 10+ Indicative of depression 
• NPI : Neuropsychiatric Inventory 
• Hallucinations • Agitation/Aggression • Depression/Dysphoria • Aberrant motor behavior [4] 
• Sleep and Nighttime Behavior Disorders • Appetite and Eating Disorders 
Gene results from TOMM40 A1, dominant allele and TOMM40 A2, recessive allele of TOMM40 gene are 
processed to identify the significant gene that contributes to the model. Hippocampus size difference from MRI 
scans of the brain is taken as significant neuroimaging input parameter to the model. 
2.1 Identifying significant test from the neuropsychological dataset 
The system performed Principal Component Analysis for dimensionality reduction on the four 
neuropsychological tests including MMSE, NPI, FAQ and GDS of patients taken over different periods of time. 
Inference: 
Our studies with 240 patients who took all 4 tests at different time intervals has revealed that FAQ, that 
determines the functional ability of the patient is more significant than MMSE, that determines the cognitive 
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ability of the patient. Subsequently, likelihood of a patient suffering from Alzheimer's is higher when functional 
activities are heavily disturbed. 
Input parameter to the system: Normalized FAQ scores given as the first input. 
2.2 Identifying significant allele from the TOMM40 gene 
Neurogenetics result set for different patients assessed from TOMM40, which was the primary Biomarker [5] 
for neurogenetic assessment was taken into consideration. TOMM40 Allele-1 and TOMM40 Allele-2 was 
clustered to identify the greater range distribution. 
 
Figure 2: Formula to compute net test scores over a period of time 
 
Figure 3: K-Means cluster on TOMM40 dataset 
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Inference: 
• Red cluster indicates patients falling in level 1-3 
• Black cluster indicates patients in level 4-7 
• TOMM40 A2, recessive gene contributes greater range in protein synthesis  
Input parameter to the system: TOMM40 A2 given as the second input. 
2.3 Calculating the hippocampus size difference 
The neuron degradation results in overall size shrinkage of human brain. The degradation initiates from 
hippocampus [6], which keeps track of all human memories and progresses slowly towards all parts of the brain. 
Since hippocampus is primarily affected, the region of MRI scan that holds hippocampus alone is segmented to 
identify size deviation in an individual over a period of time [7]. 
The following steps are involved in the process: 
1. Neuro-image segmentation using Convolutional Neural Network (CNN) algorithm [8] 
2. Laplacian transform to normalize segmented image 
3. Detection of edges on normalized image 
4. Detection of corners with edges detected 
5. Calculation of size difference with corners detected.  
 
Figure 4: Steps involved in processing MRI images 
Input parameter to the system: Size difference observed 
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3. Final Feed to the model 
Problem Type: 
 Supervised Classification 
Inputs: Normalized FAQ scores, TOMM40_A2 results, size difference 
Outputs: Binary classifier (0/1) 
 
Independent classifier was highly decorrelated with dependent features and hence algorithms that best fit the 
decorrelated dataset was chosen. The model was trained with Random Forests algorithms with close to 244 
patient records. .  
Hypothesis:  
                     T 
P(c|v) = 1/T ∑ pt(c|v) 
                    t=1 
Table 1: Training data summary 
 
 
 
Table 2: Test data summary 
Test Patient record count 200 
Actual Patients with Alzheimer's 194 
Actual Patients without Alzheimer's 6 
Table 3: Machine predicted data summary 
Test Patient record count 200 
Predicted Patients with Alzheimer's 193 
Predicted Patients without Alzheimer's 7 
Training Patient record count 844 
Patients with Alzheimer's 630 
Patients without Alzheimer's 214 
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4. Results 
A test set of 200 patients with 194 affected and 6 non-affected was fed to the system and the model 
predicted 193 records accurately.  
Error percentage = 0.83% 
Prediction Accuracy = 99% 
System proposes a new technique of integrating the neuroimaging, neuropsychological and neuro-genetic 
datasets of a patient and has a successful prediction rate of 99% (z-value: -1.5) 
5. Conclusion 
The system will assist physicians to predict Alzheimer’s accurately. 
Overall benefits achieved from the system include: 
• Isolating significant features from least significant tests 
• Integrating these significant isolated features 
• Interpreting Alzheimer’s in a patient 
Limitations of the system: 
• Severity of the disease (Mild or moderate or severe) cannot be assessed by the system 
• Limited spatial resolution of MRI scans might result in slight deviation of size differences observed 
6. Future 
Apart from the three datasets, the system can be trained with neurochemical test results and neurophysiological 
test results [9]. The system can also be trained with clinical trials performed on various patients. Adding all 
these parameters to the system will improve the prediction accuracy further. 
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